「転移したホルモン感受性前立腺がんの治療におけるアンドロゲン遮断療法へのアビラテロンの追加」がコクラン 日本語版ウェブサイトに掲載されました。 https://t.co/EWGR1xSlmq https://t.co/Aq4L3Sf3gC https://t.co/bdiffKcuMU
RT @CochraneJapan: 転移したホルモン感受性前立腺がんの治療におけるアンドロゲン遮断療法へのアビラテロンの追加 https://t.co/PciOEf1cQk
転移したホルモン感受性前立腺がんの治療におけるアンドロゲン遮断療法へのアビラテロンの追加 https://t.co/PciOEf1cQk
RT @CochraneUK: What is the effect of adding abiraterone, in men with prostate cancer, who were receiving and still responding to hormone t…
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer - Sathianathen, NJ - 2020 | Cochrane Library https://t.co/ZLMm0NvLC1
RT @CochraneLibrary: What is the effect of adding abiraterone, in men with prostate cancer, who were receiving and still responding to horm…
What is the effect of adding abiraterone, in men with prostate cancer, who were receiving and still responding to hormone therapy? https://t.co/N54DyJqGan @CochraneUrology systematic review includes 2 RCTs, with 2201 participants, certainty of the evidence
Cochrane Review: Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate #cancer https://t.co/IizvymY8vO #prostatecancer
What is the effect of adding abiraterone, in men with prostate cancer, who were receiving and still responding to hormone therapy? https://t.co/bsxKxGq8mI @CochraneUrology systematic review includes 2 RCTs, with 2201 participants, certainty of the evidence